A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: Results from the FAMOUS study

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 3, 2014, Pages 362-370

  Goebell, P J ^a   Munch A ^b   Muller L ^c   Hurtz, H J ^d   Koska, M ^e   Busies, S ^f   Marschner, N ^f  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Centre for Urology   (Germany)

^c Oncology Outpatient Centre   (Germany)

^d Joint practice for Oncology ^*  (Germany)

^e iOMEDICO   (Germany)

^f Outpatient Centre for Interdisciplinary Oncology and Haematology   (Germany)

Author keywords

Carcinoma; Fatigue; Quality of life; Questionnaires; Registries; Renal cell; Self report; Topic category: Genitourinary cancer

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; NICOTINAMIDE; PYRROLE DERIVATIVE; RAPAMYCIN;

ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EUROQOL DESCRIPTIVE SYSTEM; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HUMAN; INCIDENCE; KARNOFSKY PERFORMANCE STATUS; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SYSTEMIC THERAPY; WELLBEING; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CHEMICALLY INDUCED; CLINICAL TRIAL; FATIGUE; KIDNEY NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CROSS-SECTIONAL STUDIES; FATIGUE; FEMALE; HUMANS; INCIDENCE; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHYSICIANS; PYRROLES; QUALITY OF LIFE; QUESTIONNAIRES; SELF REPORT; SIROLIMUS;

EID: 84897082501     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.09.009     Document Type: Article

References (31)

1. Husmann G, Kaatsch P, Katalinic A, Bertz J, Haberland J, Kraywinkel K. u. a. Niere und ableitenden Harnwege. Krebs in Deutschland 2005/06. Häufigkeiten und Trends. Berlin: Robert Koch Institut pp. 80-3.
2. Bellmunt J., Fishman M., Eisen T., Quinn D. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther 2010, 10:825-835.
3. Slevin M.L., Plant H., Lynch D., Drinkwater J., Gregory W.M. Who should measure quality of life, the doctor or the patient?. Br J Cancer 1988, 57:109-112.
4. Sneeuw K.C.A., Aaronson N.K., Sprangers M.A.G., Detmar S.B., Wever L.D.V., Schornagel J.H. Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses. Br J Cancer 1999, 81:87-94.
5. Choueiri T.K., Duh M.S., Clement J., Brick A.J., Rogers M.J., Kwabi C. u. a. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int 2010, 105:1247-1254.
6. Ivanyi P., Winkler T., Ganser A., Reuter C., Grünwald V. Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. Dtsch Arztebl Int 2008, 105:232-237.
7. Schmidinger M., Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010, 36:416-424.
8. Flechtner H., Bottomley A. Fatigue and quality of life: lessons from the real world. Oncologist 2003, 8:5-9.
9. Cella D.F., Tulsky D.S., Gray G., Sarafian B., Linn E., Bonomi A. u. a. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11:570-579.
10. Webster K., Cella D., Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003, 1:79.
11. Rabin R., de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001, 33:337-343.
12. Müller L., Münch A., Blumenstengel K., Sauer U., Goebell P., Hipper A. Treatment of patients with advanced or metastatic renal cell carcinoma (RCC-Registry): a "Real LIFE" treatment overview of non-trial patients in outpatient cancer centres in Germany. Onkologie 2009, 32(Suppl. 4):243.
13. Nierenzellkarzinom Leischner H. Onkologie 2010, 52-53. Urban & Fischer, München. 2nd ed.
14. Mathias C., Cardeal Mendes C.M., Pondé de Sena E., Dias de Moraes E., Bastos C., Braghiroli M.I., et al. An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer. Ann Oncol 2006, 17:1792-1796.
15. Eton D.T., Cella D., Yost K.J., Yount S.E., Peterman A.H., Neuberg D.S., et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004, 57:898-910.
16. Blazeby J.M., Farndon J.R., Donovan J., Alderson D. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer 2000, 88:1781-1787.
17. Rothwell P.M., McDowell Z., Wong C.K., Dorman P.J. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. Br Med J 1997, 314:1580-1583.
18. Sigurdardóttir V., Brandberg Y., Sullivan M. Criterion-based validation of the EORTC QLQ-C36 in advanced melanoma: the CIPS questionnaire and proxy raters. Qual Life Res 1996, 5:375-386.
19. Sprangers M.A.G., van Dam F.S.A.M., Broersen J., Lodder L., Wever L., Visser M.R.M. u. a. Revealing response shift in longitudinal research on fatigue: the use of the thentest approach. Acta Oncol 1999, 38:709-718.
20. Sprangers M.A., Aaronson N.K. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol 1992, 45:743-760.
21. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R. u. a. Sunitinib in patients with metastatic renal cell carcinoma. J Am Med Assoc 2006, 295:2516-2524.
22. Kane R.C., Farrell A.T., Saber H., Tang S., Williams G., Jee J.M. u. a. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006, 12:7271-7278.
23. Kollmannsberger C., Soulieres D., Wong R., Scalera A., Gaspo R., Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007, 1(Suppl. 2):S41-S54.
24. Ludwig H., Van Belle S., Barrett-Lee P., Birgegård G., Bokemeyer C., Gascón P. u. a. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004, 40:2293-2306.
25. Borneman T., Piper B.F., VC-Y S.u.n., Koczywas M., Uman G., Ferrell B. Implementing the Fatigue Guidelines at one NCCN member institution: process and outcomes. J Natl Compr Canc Netw 2007, 5:1092-1101.
26. Shun S.-C., Lai Y.-H., Hsiao F.-H. Patient-related barriers to fatigue communication in cancer patients receiving active treatment. Oncologist 2009, 14:936-943.
27. Stone P., Richardson A., Ream E., Smith A.G., Kerr D.J., Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000, 11:971-975.
28. Berger A.M. Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncol Nurs Forum 1998, 25:51-62.
29. Higgins S.C., Montgomery G.H., Raptis G., Bovbjerg D.H. Effect of pretreatment distress on daily fatigue after chemotherapy for breast cancer. J Oncol Pract 2008, 4:59-63.
30. Jacobsen P.B., Hann D.M., Azzarello L.M., Horton J., Balducci L., Lyman G.H. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 1999, 18:233-242.
31. Holzner B., Kemmler G., Meraner V., Maislinger A., Kopp M., Bodner T. u. a. Fatigue in ovarian carcinoma patients. Cancer 2003, 97:1564-1572.